Publikationer

Under åren har medlemmarna producerat ett stort antal publikationer. Några av dem kan ni läsa och eventuellt beställa från Svenska Migränsällskapet. Välj i menyn till höger.

Higher socioeconomic status is associated with dispensation of monoclonal antibodies against calcitonin gene-related peptide in migraine: A nested case-control study

CephalalgiaVolume 45, Issue 6, June 2025
© International Headache Society 2025, Article Reuse Guidelines
https://doi.org/10.1177/03331024251348648
  1. Background
    Higher socioeconomic status (SES) among people with migraine has been associated with an increased use of triptans, but it is undetermined whether high SES is also associated with dispensation of monoclonal antibodies against calcitonin gene-related peptide (CGRPi), a prophylactic treatment against migraine episodes. Our hypothesis was that higher SES is associated with CGRPi dispensation, although the association is expected to be attenuated in a country that generally allows for reimbursement of CGRPi costs.
    Methods
    In this register-based nested case-control study, the association between SES, categorized into three levels (low, middle and high) and the outcome of a first dispensation of a CGRPi was assessed among people with a migraine diagnosis in Region Stockholm, using univariable and multivariable logistic regression models.
    Results
    Of 52,996 individuals in the study population, 3.2% (n = 1674) were dispensed CGRPi. Individuals with high or middle SES had an increased probability of being dispensed CGRPi, compared to individuals with low SES (adjusted odds ratio = 1.68; 95% confidence interval = 1.46–1.92 and adjusted odds ratio = 1.41; 95% confidence interval = 1.24–1.61, respectively).
    Conclusions
    Higher SES was associated with dispensation of CGRPi, which suggests unequal access to CGRPi.
 
 
  1. Prescriber adherence to treatment guidelines for monoclonal antibodies against Calcitonin Gene-Related Peptide in migraine prophylaxis – a register-based cohort study Sofia Nordenmalm1,2*, Rickard E. Malmström1,2, Sara Freyland1,3, A. Ingela M Nilsson Remahl4,5, Karin Wirdefeldt4,5,6† and Isabella Ekheden2,7†
    Abstract
    Background
    Calcitonin Gene-Related Peptide targeting monoclonal antibodies (CGRP mAbs) were introduced for migraine prophylaxis in Sweden through the National Joint Introduction process to ensure an equal, cost-effective, and appropriate national use. This study aimed to assess prescriber adherence to treatment guidelines and evaluate patient treatment persistence during the national introduction of CGRP mAbs.
    Methods In this register-based cohort study, we followed individuals with a migraine diagnosis or dispensation of migraine drugs within Stockholm County from July 2018 to June 2022. We evaluated the guidelines for CGRP mAb treatment (erenumab, fremanezumab, or galcanezumab) according to four categories: 1) patient eligibility, 2) prescriber qualifications, 3) treatment evaluation, and 4) monitoring/reporting. We used a Sankey diagram to illustrate treatment switching and discontinuation patterns and employed boxplots along with Kaplan-Meier estimates to assess the persistence to CGRP mAbs.
    Results Among 93,263 eligible individuals, 2266 (2%) had at least one CGRP mAb dispensation. Most (90%) had a prior migraine diagnosis at the first CGRP mAb dispensation, and 66% had been dispensed at least two prior prophylactic drugs against migraine. In nearly all cases (97%), CGRP mAb prescriptions were issued by neurology or headache specialists. Switching between CGRP mAbs was common and treatment persistence declined across successive sequences. Overall median treatment duration was 5.8 months (interquartile range: 2.8–11.9 months) and was longer for erenumab than fremanezumab and galcanezumab in sequence 1, but not in sequence 2. Kaplan Meier analysis revealed a 12-month persistence of 58% in sequence 1, 53% in sequence 2, and 46% in sequence 3. A higher persistence was observed for fremanezumab and galcanezumab compared with erenumab in sequence 1, while estimates were similar in sequence 2

IHE-rapporten om kvinnors hälsa 2025.

https://ihe.se/rapport/fallstudier-om-flickors-och-kvinnors-halsa/

Doktorsavhandling av Andrea Carmine Belin

Deciphering the role of genetics and circadian rhythm in cluster headache

Carmen Fourier Doktorsavhandling Karolinska Institutet 2021; 

Länk: https://openarchive.ki.se/xmlui/handle/10616/47618

Lägg till din rubriktext här